OpenAlex 2.601 eser 108 yazar konusu
Çalışmalar
2.601 eser
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: Establishing cardiovascular safety of new therapies for type 2 diabetes is important. Safety data are available for the subcutaneous form of the glucagon-like peptide-1 receptor agonist semaglutide but are needed for oral semaglutide. METHODS: We assessed cardiovascular outcomes of once-daily oral semaglut…
Akademisyenler
108 akademisyen
- ABDULLAH ŞİŞİK 36 yazar konusu
- OZAN ŞEN 32 yazar konusu
- ANIL ERGİN 22 yazar konusu
- HASAN ERDEM 22 yazar konusu
- FATİH SÜMER 21 yazar konusu
- HAKAN SEYİT 21 yazar konusu
- MUSTAFA TAŞKIN 21 yazar konusu
- SERDAR YORMAZ 19 yazar konusu
- İLHAN ECE 18 yazar konusu
- MEHMET CELAL KIZILKAYA 16 yazar konusu
- BAYRAM ÇOLAK 15 yazar konusu
- FAHRETTİN ACAR 15 yazar konusu